The New Vaccine Factory in Norway GMP/ISO Manufacturing of Vaccines, Therapeutics, and Diagnostics for COVID-19, Infectious Disease and Sustained Innovation in Pandemic Preparedness GOAL:
Opening up leading science, discovery and technology for global public health and pandemic preparedness.

OUR MISSION

Participating as a strategic partner in the global ecosystem for the transformative development and manufacture of vaccines and biological medicinal products for global public health and future pandemic preparedness.

Norsk Vaksinefabrikk at Borgeskogen 65, Sandefjord. 

Norsk Vaksinefabrikk is located in the industrial park at Borgeskogen, Sandefjord, 12 minutes from TORP international airport for global access to highly profitable and sustainable biopharmaceutical export service products for COVID-19, infectious disease and global epidemic preparedness – truly a ‘forever market need’.

The First Vaccine Factory in Norway for Pandemic Preparedness

With a focus on partnership and open science we are developing the future of biological medicines through shared scientific expertise, agility and innovation, for the COVID-19 pandemic and long-term sustained pandemic preparedness. Our vision is to create an ecosystem for biological medicines, ‘Norsk Vaksinefabrikk’, where research and development will co-exist with established GMP manufacturing.

Production/logistics building with associated offices:  12,733 sqm. 

  • 8,930 sqm. high  ceiling warehouse /logistics/production 
  • 2,553 sqm. offices on two levels
  • 1,250 sqm. common area (technical, training room, locker rooms) 
  • Easy access and maneuverability areas for heavy transport. 
  • Flexible premises with many access points. 
  • Multiple ramps and gates around the building. Very good access around the building for trucks and large vehicles. Parking in excess.

OUR FOCUS

Norsk Vaksinefabrikk focus for 2021 is rapid long-term growth, achieved through short- and long-term pandemic strategies. Our manufacturing solutions support the current COVID-19 pandemic with an industrial scale infrastructure. We plan to deliver sustained pandemic preparedness through open science research and development in Norway, the UK and EU. As a social enterprise our goal is to provide affordable solutions to deliver high impact for global public health. Our unique export products and services in development include:

VACCINES

Developing and manufacturing of mRNA vaccines with Lipidnanoparticle (LNP) delivery for COVID-19, infectious diseases and disease therapeutics

FILL-FINISH

Fill-finishing for Vaccines and Therapeutics
for COVID-19
and Pandemic Preparedness

TESTS

Developing and manufacturing advanced, low cost,
rapid diagnostics
for viral infections, including COVID-19

TREATMENTS

Developing and manufacturing of treatments for infectious disease and pandemic preparedness (long term growth phase)

mRNA Vaccine Technology and Industrial Scale Manufacturing

Transformative future opportunities for biomedical innovations with Norsk Vaksinefabrikk

Over the past 60 years, scientists have learned how to use mRNA to develop a new category of medicines which have recently been proven to be transformative for preventing infection and disease in the COVID-19 pandemic.

NORVAX UK, with the mRNA UCV Consortium and Norsk Vaksinefabrikk, is leveraging the fundamental role that mRNA plays in protein synthesis to develop the mRNA Universal Coronavirus Vaccine (mRNA UCV) for the SARS-CoV-2 virus which causes COVID-19 disease. NORVAX UK and the mRNA UCV Consortium are “programming” the harmless “spike” portion of the SARS-CoV-2 virus for the planned manufacturing into mRNA molecules with encapsulation into Lipid nanoparticles (LNPs), for an mRNA UCV product, to stimulate immunity in the event of SARS-CoV-2 infection by so-called “Variants of Concern” including the Alpha, Beta, Gamma, Delta. Industrial scale production of mRNA UCV is planned to be delivered by Norsk Vaksinefabrikk by Norvax AS in 2022/23.

Industrial Scale Manufacturing and Fill-finish

Norsk Vaksinefabrikk is commissioning and deploying in Sandefjord the most advanced vaccine fill-finish manufacturing system in Norway.

The Norsk Vaksinefabrikk fill-finish production line is capable of  36,000 2R vials per hour.

In a 10R vial, at 0.5ml per dose, Norsk Vaksinefabrikk capacity is planned to be up to 289,000,000 vaccine doses per month, representing an emergency pandemic preparedness priority fill-finish capacity of up to 5 million vaccine doses in less than 24 hours from delivery of bulk vaccine supply.

Norsk Vaksinefabrikk by Norvax AS is a social enterprise located in Borgeskogen industrial park, Sandefjord, 12 minutes from TORP international airport, for rapid global access.

Norvax focus is on long-term sustained growth and business development in the international biopharmaceutical industry. The Norvax growth plan will create high value employment opportunities in Vestfold og Telemark, Sandefjord, Tønsberg, and Norway. 

Slide Norvax Fast-Test for COVID-19
with CHEC Mobile App
GOV UK functional validation by DHSC at Porton Down The results of the Norvax Fast-Test for COVID-19 may be recorded for optional sharing with public health authorities to the free, private and secure mobile app: CHEC (Covid Health Examined Health Certificate). Norvax Fast-Test for COVID-19 is a rapid test with saliva sample, to enable people to safely enter into controlled or confined social environments, such as Care Homes, Theatres, Event Venues, Movie Theatres, and Airplanes, knowing all participants were free of SARS-CoV-2 viral load, prior to entry.

Strategic Technology Partners and Preferred Vendors

Norsk Vaksinefabrikk is the lead industrial scale manufacturing member of:

NORVAX UK Limited founded the mRNA UCV Consortium with the mission to develop and manufacture an mRNA Universal Coronavirus Vaccine (mRNA-UCV) at industrial scale for COVAX/ACT/GAVI and HIC Customers for delivery in 2022/23 on Advance Purchase Agreements (APA) by sponsors, governments and industry customers. The mission of mRNA UCV Consortium is to help end the COVID-19 pandemic and to support pandemic preparedness for future outbreaks.

LEARN MORE

The Research Council of Norway has granted a NOK 16.000.000 research and development innovation project to Norvax AS.

Project Title:
Development of a lipid nanoparticle platform for mRNA Formulation.

Norvax will cooperate with SINTEF to develop NORVAX-LNP – the mRNA LNP Product Formulation – which will become a strategic technology component of the mRNA Vaccine Platform by Norsk Vaksinefabrikk.

LEARN MORE

CALL TO ACTION

WARNING. PANDEMICS ARE DEADLY. IT IS NOT OVER. COMPLACENCY IS DEADLY.
MERS Coronavirus Case Fatality Rate is 35%. One in three infections result in DEATH.
Likelihood of increased [SARS-CoV-2] severity phenotype: Realistic possibility. (SAGE)
VERY IMPORTANT SCIENTIFIC DISCLOSURES!